Abstract
Objective (1) to test the association with prevalent and incident atrial fibrillation (AF), and prognosis of total N-terminal pro-B type natriuretic peptide (total NT-proBNP) and of a panel of biomarkers; (2) to assess iwhether the extent of glycosylation affects the relation of NT-proBNP with AF.
Methods In a sub-study of the GISSI-AF trial on 382 patients in sinus rhythm with a history of AF, echocardiographic variables and eight circulating biomarkers were serially assayed over one year. The relations between circulating baseline biomarkers and AF and the risk of CV events, were assessed by Cox-analysis models adjusting the first by clinical variables, the second by clinical variables and the echocardiographic left-atrial-minimum-volume-index (LAVImin).
Results Over a median follow-up of 365 days, 203/382 patients (53.1%) had at least one recurrence of AF and 16.3% were hospitalized for cardiovascular (CV) reasons. Total NT-proBNP, NT-proBNP, angiopoietin 2 (Ang2), myosin binding protein (MyBPC3) and bone morphogenic protein-10 (BMP-10) were strongly associated to ongoing AF. Natriuretic peptides and MyBPC3 predicted recurrent AF but this lost significance after adjustment for LAVImin. NT-proBNP and Ang2 predicted CV hospitalization even after adjustment for LAVImin, HR95%CI: 2.20 [1.02-4.80] and 5.26 [1.16-23.79].
Conclusions The association of AF recurrence with the novel biomarker total NT-proBNP, is similar to that of NT-proBNP, suggesting no influence of glycosylation. Ang2, MyBPC3 and BMP10 were strongly associated with AF, indicating a possible role of extracellular matrix and myocardial injury. Abstract-words=233
What is already known on this subject?It is still complicated to predict the recurrence of AF in patients in sinus rhythm with a recent history of AF. Though several biomarkers have been associated with AF, few of them have proved to be independent predictors for recurrent AF or cardiovascular (CV) events. Their predictive sensitivity and specificity is modest at best. Previous studies showed that NT-proBNP was possibly the strongest predictor of recurrent AF and CV hospitalization. Natriuretic peptides circulate to a large extent as glycosylated molecules and a novel assay is now available to measure the glycosylated and non-glycosylated NT-proBNP in plasma, the total NT-proBNP. The extent of glycosylation varies in different diseases.
What might this study add?No studies have assessed (a) the extent of NT-proBNP glycosylation in AF, or (b) the association and predictive value in patients with AF of total NT-proBNP. A multimarker approach, ratter than one based on a single biomarker, might predict AF better.
The relation with AF of the novel biomarker, total NT-proBNP, is as strong as that of NT-proBNP, suggesting no-influence of glycosylation.
Two biomarkers, MyBPC3, secreted few minutes after myocardial injury and Ang-2, involved in inflammation and coagulation, were strongly associated to AF.
How might this impact on clinical practice?The identification of novel circulating biomarkers could have a direct impact on clinical practice when predicting the occurrence of AF, but unfortunately current data do not allow predictions based on biomarkers.
The associations of different biomarkers with ongoing AF may cast light on the mechanisms of triggering and maintenance of AF.
Strengths and limitations of this study The data came from to a multicenter randomized clinical trial with available concomitant serial echocardiographic and circulating biomarkers recorded and evaluated centrally, hence with minimal bias; AF recurrence during a 12-month follow up was checked weekly by trans-telephonic electrocardiographic monitoring, and with 12-lead ECG every six months.
A comparative analysis of total NT-proBNP with other novel biomarkers and echocardiographic variables has never been done so far. The possible added value of total NT-proBNP to the benchmark biomarker NT-proBNP was assessed on the basis of different dimensions of performance, as recently proposed for new biomarkers. The main limitations are (1) the relatively small numbers of patients with AF during follow-up visits, (2) the very low prevalence of patients with other cardiac diseases such as coronary artery disease and heart failure, and (3) consequently, the low incidence of clinical events in one-year follow-up.
Competing Interest Statement
SM, LS, APM, MGF, MD and RL received institutional research support from Novartis Pharma and Roche Diagnostics. UHW-T is an employee of Roche Diagnostics GmbH, Penzberg, Germany, the company that funded part of the present study.SM is currently an employee of Roche Diagnostics International, Rotkreuz, Switzerland.
Clinical Trial
Clinical Trials.gov identifier: NCT00376272
Clinical Protocols
https://eudract.ema.europa.eu/
Funding Statement
The GISSI studies and this substudy are supported by the Associazione Nazionale Medici Cardiologi Ospedalieri and by the Istituto di Ricerche Farmacologiche Mario Negri IRCCS. Novartis Pharma Italy funded the GISSI-AF trial. The substudy was partially supported by Roche Diagnostics GmbH Penzberg, Germany. The funders had no role in the design and conduct of the study; data collection, management, analysis and interpretation; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Comitato Etico Cantonale 6501 Bellinzona Canton Ticino for Servizio di Cardiologia Cardiocentro Ticino Lugano Canton Ticino Switzerland Approval date February 22 2006 Comitato Etico per la Sperimentazione Clinica dei Medicinali Azienda Sanitaria di Firenze for UO Cardiologia Ospedale Santa Maria Annunziata Firenze Italy Approval date October 27 2005 Comitato Etico Regione Puglia Azienda Unita Sanitaria Locale BA4 Bari for UO Cardiologia Ospedale Di Venere Bari Italy Approval date October 10 2004 Comitato di Bioetica dell Azienda Ospedali Riuniti di Bergamo Bergamo for USC Cardiologia Bergamo Italy Approval date April 18 2005 Comitato Etico per la Sperimentazione Clinica dei Medicinali Regione Veneto ULSS 21 di Legnago for UOC di Cardiologia Servizio di Benevento Verona Italy Approval date January 18 2005 Comitato Etico per la Sperimentazione Clinica dei Medicinali Regione Veneto ULSS 22 di Bussolengo for UOC di Cardiologia Ospedale di Bussolengo Verona Italy Approval date December 12 2004 Comitato Etico Indipendente Servizio Sanitario della Puglia for UO Cardiologia Presidio Ospedalieri Casarano Scorrano Italy Approval date December 1 2004 Comitato Etico Regione Campania Azienda Ospedaliera San Sebastiano di Caserta di Rilievo Nazionale e di Alta Specializzazione for UO UTIC Ospedale di Caserta Napoli Italy Approval date October 14 2004 Comitato Etico Dell Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi S Luigi Curro Ascoli Tomaselli Catania for UO Cardiologia POS Luigi Curro Catania Sicilia Italy Approval date November 11 2004 Comitato di Bioetica Azienda Ospedaliera Mater Domini e Facolta di Medicina e Chirurgia for UO Cardiologia Catanzaro Italy Approval date December 1 2004 Comitato Etico CEAS Umbria Azienda Sanitaria for Servizio di Cardiologia Ospedale Civile di Gubbio Perugia Italy Approval date December 21 2004 Comitato Etico Regione Lombardia Istituti Ospedalieri di Cremona Azienda Ospedaliera 030957 for UO Cardiologia Presidio Ospedaliero di Cremona Italy Approval date February 8 2005 Comitato Etico Servizio Sanitario Regionale Emilia Romagna Azienda Unita Sanitaria Locale di Parma for Unita Operativa Cardiologia Presidio Ospedaliero Fidenza San Secondo Pse Fidenza Parma Italy Approval date May 3 2005 Comitato Etico per la Sperimentazione Clinica dei Medicinali Azienda Sanitaria di Firenze for UO Cardiologia Ospedale Nuovo San Giovanni di Dio Firenze Italy Approval date October 27 2005 Comitato Etico per le Attivita Biomediche Universita degli Studi Di Napoli Federico II for Reparto di Cardiologia dell Ospedale Policlinico Federico II di Napoli Napoli Italy Approval date May 10 2005 Comitato Etico Azienda Ospedaliera V Cervello Palermo Sicilia for Reparto di Cardiologia Ospedale Vincenzo Cervello Palermo Sicilia Italy Approval date October 10 2004 Comitato Etico Azienda Ospedaliera Villa Sofia CTO Palermo Sicilia for UO Cardiologia Ospedale Villa Sofia CTO Palermo Sicilia Italy Approval date May 5 2005 Comitato Bioetico IRCCS Policlinico San Mateo Pavia for IRCCS Policlinico San Mateo Pavia Italy Approval date October 18 2004 Comitato Etico Regione Marche Azienda Ospedaliera San Salvatore Pesaro for SOC Cardiologia Azienda Ospedaliera Ospedale San Salvatore Pesaro Italy Approval date October 26 2004 Comitato Etico Regione Liguria Azienda Ospedaliera Ospedale Santa Corona Pietra Ligure Savona for Ospedale Santa Corona Pietra Ligure Savona, Italy Approval date December 22 2004 Comitato Etico Regione Calabria ASL 11 Reggio Calabria for Servizio di Cardiologia Ospedale Scillesi d America e Policlinico Madonna della Consolazione Reggio Calabria Italy Approval date November 26 2004 Comitato Etico dell Azienda Ospedaliera Sant Andrea Roma for Ospedale Sant Andrea Roma Italy Approval date December 3 2004 Comitato Etico Azienda Ospedaliera Croce e Carle Cuneo Italy for UO di Medicina Ospedale di Saluzzo Cuneo Italy Approval date May 18 2006 Comitato Etico Regione Veneto ULSS 20 di Verona for UO Cardiologia Ospedale S Bonifacio Verona Italy Approval date January 18 2005 Comitato Etico Indipendente Facolta di Medicina e Chirurgia Universita degli Studi di Udine for Cardiologia Ospedale S Daniele ASS 4 Medio Friuli Italy Approval date January 24 2005 Comitato Etico SSN Azienda Sanitaria 2 Castrovillari for UO di Medicina Interna del PO di S Marco Argentano Reggio Calabria Italy Approval date July 26 2005 Comitato Etico Servizio Sanitario Nazionale Regione Liguria Azienda Unita Sanitaria Locale 5 Spezzino La Spezia for UO Cardiologia Riabilitativa Ospedale S Bartolomeo di Sarzana La Spezia Italy Approval date January 13 2005 Comitato Etico delle Aziende Sanitarie dell Umbria for ASL Terni Azienda Sanitaria for UO Cardiologia Territoriale Azienda USL 4 Terni Italy Approval date October 7 2004 PARERE UNICO della Commissione per le Sperimentazioni Cliniche della APS del Trentino for UO Cardiologia POS Chiara di Trento Italy Approval date September 30 2004 Commissione per le Sperimentazioni Cliniche della APSS del Trentino for UO di Cardiologia della Casa di Cura Privata Villa Bianca Trento Italy Comitato Etico Indipendente ASS 1 Triestina for UO Centro Cardiovascolare di Trieste Italy Approval date May 30 2005 Comitato Etico Servizio Sanitario Regionale Azienda Ospedaliero Universitaria Ospedale Riuniti di Trieste for UO di Cardiologia Ospedale Riuniti di Trieste Italy Approval date June 26 2006
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The entire database of GISSI-AF can be accessed upon reasonable request to the Steering Committee.
Glossary
- GISSI-AF trial
- Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico–Atrial Fibrillation trial
- ARISTOTELE trial
- Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation
